SCOR delivers a strong performance for the first quarter 2014 with a net income of EUR 135 million, up 21.6%

Les renouvellements du 1er avril de SCOR Global P&C se traduisent par une croissance des primes de 8,5 %, avec une rentabilité anticipée conforme aux objectifs fixés

The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets.

The SCOR Global P&C 1 April renewals lead to premium growth of 8.5% with expected profitability well within targets

The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

In December 2013 the Critical Illness Defi nitions and Geographical Variations Working Party presented their paper, ‘Extending the Critical Path’ to the Staple Inn Actuarial Society.

Winner of the Actuarial Award in Asia, 2013

En 2013, une neurologie conquérante et innovante voit le jour : la génétique, la biotechnologie, l’imagerie médicale, la neurochirurgie, l’industrie pharmaceutique… les recherches fondamentales et cliniques s’allient

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting

In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting